If we're not the right fit, we'll tell you
Singhs overall message was that current evidence does not support withholding GLP-1 therapy solely because of ocular safety concerns
For a novel compound like 5-amino-1MQ, microdosing could be an appropriate strategy, as it may provide insights into the compound's metabolism, biological activity, and safety profile
JACC Heart Fail 11:10001010 Hollstein T, Schlicht K, Krause L et al (2021) Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure
He breaks down the different concentrations of the ingredient and how they work
Anti-factor Xa activities of zingerone with anti-platelet aggregation activity